Natco Sorafenib Sorafenat 200mg*120 tablets Hepatocellular carcinoma, renal cell carcinoma, thyroid cancer, gastrointestinal stromal tumor, desmoid tumor, angiosarcoma, solitary fibrous tumor,

Drug Name
Generic name: Sorafenib tosylate tablets

English name: Sorafenib Tosylate Tablets

Indications
Treatment of inoperable advanced renal cell carcinoma.

Treatment of inoperable or distant metastatic hepatocellular carcinoma.


There is a lack of randomized controlled trials comparing sorafenib with hepatic artery chemoembolization (TACE) and other There is a lack of data from randomized controlled clinical studies comparing sorafenib to interventional therapy in patients with advanced hepatocellular carcinoma, such as hepatic artery chemoembolization (TACE), and therefore it is not possible to determine the advantages or disadvantages of this product compared to interventional therapy, or whether the use of sorafenib is beneficial in patients with prior interventional therapy (see [Clinical Trials] item). Physicians are advised to consider the patient's specific situation and select the appropriate treatment.

Treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer.

Dose
Recommended Dose

The recommended dose of sorafenib is 0.4 g (2 x 0.2 g) twice daily on an empty stomach or with a low-fat or moderate-fat diet.


Use


Take orally with a glass of warm water.

Treatment duration

Treatment should be continued until the patient fails to achieve clinical benefit or develops an intolerable toxic reaction.

Adverse Reactions
The most common drug-related adverse events reported in patients treated with sorafenib were rash (38%), diarrhea (37%), skin reactions of the hands and feet (35%), and malaise (33%).

Storage
Store in a tightly closed container at temperatures below 25°C.Keep out of the reach of children. Keep out of reach of children. Keep out of the reach of children.